Akebia Therapeutics
Market Cap
US$762.4m
Last Updated
2019/12/11 00:41 UTC
Data Sources
Company Financials +
Executive Summary
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
Snowflake Analysis
Adequate balance sheet with moderate growth potential.
Similar Companies
Share Price & News
How has Akebia Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AKBA's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
6.8%
AKBA
0.1%
US Biotechs
1.1%
US Market
1 Year Return
-28.3%
AKBA
14.7%
US Biotechs
17.8%
US Market
Return vs Industry: AKBA underperformed the US Biotechs industry which returned 14.7% over the past year.
Return vs Market: AKBA underperformed the US Market which returned 17.8% over the past year.
Shareholder returns
| AKBA | Industry | Market | |
|---|---|---|---|
| 7 Day | 6.8% | 0.1% | 1.1% |
| 30 Day | 75.1% | 9.0% | 1.4% |
| 90 Day | 21.9% | 15.2% | 3.9% |
| 1 Year | -28.3%-28.3% | 15.7%14.7% | 20.3%17.8% |
| 3 Year | -18.6%-18.6% | 28.4%24.3% | 44.8%35.4% |
| 5 Year | -46.0%-46.0% | 10.2%5.0% | 71.3%52.4% |
Price Volatility Vs. Market
How volatile is Akebia Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
What You Must Know About Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Beta Value2 weeks ago | Simply Wall St
John Butler Is The CEO, President & Director of Akebia Therapeutics, Inc. (NASDAQ:AKBA) And They Just Spent US$172k On Shares3 weeks ago | Simply Wall St
US$15.38: That's What Analysts Think Akebia Therapeutics, Inc. Is Worth After Its Latest ResultsValuation
Is Akebia Therapeutics undervalued compared to its fair value and its price relative to the market?
1.63x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AKBA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AKBA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AKBA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: AKBA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AKBA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AKBA is good value based on its PB Ratio (1.6x) compared to the US Biotechs industry average (3.2x).
Next Steps
Future Growth
How is Akebia Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
59.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AKBA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: AKBA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AKBA's is expected to become profitable in the next 3 years.
Revenue vs Market: AKBA's revenue (4.8% per year) is forecast to grow slower than the US market (7.4% per year).
High Growth Revenue: AKBA's revenue (4.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AKBA's Return on Equity is forecast to be low in 3 years time (5.8%).
Next Steps
Past Performance
How has Akebia Therapeutics performed over the past 5 years?
-18.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AKBA is currently unprofitable.
Growing Profit Margin: AKBA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AKBA is unprofitable, and losses have increased over the past 5 years at a rate of -18.5% per year.
Accelerating Growth: Unable to compare AKBA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AKBA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).
Return on Equity
High ROE: AKBA has a negative Return on Equity (-52.45%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Akebia Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: AKBA's short term assets ($299.0M) exceed its short term liabilities ($223.1M).
Long Term Liabilities: AKBA's short term assets ($299.0M) exceed its long term liabilities ($104.5M).
Debt to Equity History and Analysis
Debt Level: AKBA is debt free.
Reducing Debt: AKBA had no debt 5 years ago.
Balance Sheet
Inventory Level: AKBA has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if AKBA's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AKBA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AKBA has less than a year of cash runway if free cash flow continues to reduce at historical rates of -93.3% each year
Next Steps
Dividend
What is Akebia Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate AKBA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate AKBA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AKBA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AKBA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AKBA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Akebia Therapeutics's salary, the management and board of directors tenure and is there insider trading?
3.6yrs
Average management tenure
CEO
John Butler (55yo)
6.3yrs
Tenure
US$3,471,072
Compensation
Mr. John P. Butler, MBA, has been the Chief Executive Officer and President of Akebia Therapeutics, Inc. since September 2013. Mr. Butler served as Chief Executive Officer of Inspiration Biopharmaceuticals ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD3.47M) is above average for companies of similar size in the US market ($USD2.64M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
3.6yrs
Average Tenure
53yo
Average Age
Experienced Management: AKBA's management team is considered experienced (3.6 years average tenure).
Board Age and Tenure
1.2yrs
Average Tenure
63.5yo
Average Age
Experienced Board: AKBA's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: AKBA insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Shares | 5,800 |
| Max Price | US$3.43 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 15,000 |
| Max Price | US$3.52 |
| Entity | Individual |
| Role | Senior Key Executive Senior VP & Chief Medical Officer |
| Shares | 27,000 |
| Max Price | US$3.58 |
| Entity | Individual |
| Role | Chief Executive Officer CEO, President & Director |
| Shares | 50,000 |
| Max Price | US$3.44 |
| Entity | Individual |
| Role | Chairman of the Board Independent Chairperson |
| Shares | 50,000 |
| Max Price | US$3.41 |
| Entity | Company |
| Shares | 99,931 |
| Max Price | US$8.61 |
| Entity | Company |
| Shares | 410,577 |
| Max Price | US$8.50 |
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 101.8%.
Management Team
John Butler (55yo)
CEO, President & Director
- Tenure: 6.3yrs
- Compensation: US$3.47m
Steven Burke (58yo)
Senior VP & Chief Medical Officer
- Tenure: 0.5yrs
Kristen Sheppard
Vice President of Investor Relations
- Tenure: 0yrs
Jason Amello (51yo)
Senior VP
- Tenure: 6.3yrs
- Compensation: US$1.09m
Karen Tubridy (57yo)
Senior VP & Chief Development Officer
- Tenure: 3.1yrs
Michel Dahan (40yo)
Senior VP & Chief Business Officer
- Tenure: 4.2yrs
- Compensation: US$1.28m
Nikki Hadas (46yo)
SVP, Chief Legal Officer & Secretary
- Tenure: 6.9yrs
Tamara Dillon
Senior Vice President of Human Resources
- Tenure: 3.1yrs
Doug Jermasek
Vice President of Marketing & Strategy
- Tenure: 0yrs
Dell Faulkingham
Senior VP & Chief Commercial Officer
- Tenure: 0.6yrs
Board Members
Suzette Dutch
Observer
- Tenure: 0yrs
Michael Rogers (59yo)
Independent Director
- Tenure: 1yrs
- Compensation: US$133.44k
Peter Hutt (84yo)
- Tenure: 0yrs
Adrian Adams (68yo)
Independent Chairperson
- Tenure: 1yrs
- Compensation: US$133.44k
John Butler (55yo)
CEO, President & Director
- Tenure: 6.3yrs
- Compensation: US$3.47m
Randall Johnson (72yo)
Advisor & Member of Scientific Advisory Board
- Tenure: 0yrs
John Adamson
- Tenure: 0yrs
Frank Bunn
- Tenure: 0yrs
Volker Haase
Advisor & Member of Scientific Advisory Board
- Tenure: 0yrs
Cynthia Smith (50yo)
Independent Director
- Tenure: 1.3yrs
- Compensation: US$154.62k
Company Information
Akebia Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Akebia Therapeutics, Inc.
- Ticker: AKBA
- Exchange: NasdaqGM
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$762.425m
- Shares outstanding: 118.94m
- Website: https://www.akebia.com
Number of Employees
Location
- Akebia Therapeutics, Inc.
- 245 First Street
- Suite 1400
- Cambridge
- Massachusetts
- 2142
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AKBA | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Mar 2014 |
| AX9 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Mar 2014 |
Biography
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a fe ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/11 00:41 |
| End of Day Share Price | 2019/12/10 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.